Early HIV infection: to treat or not to treat?
- Quality-of-Life Evaluation in a Clinical Trial of Zidovudine Therapy in Patients with Mildly Symptomatic HIV Infection. Gelher, Richard D.; Lenderking, William R.; Cotton, Deborah J.; Cole, Bernard F.; Fischl, Margaret A.; Goldhirsch, Aron; Testa, Marcia A. // Annals of Internal Medicine;6/15/92 Part 1, Vol. 116 Issue 12, p961
Presents a study which evaluated the effects of zidovudine therapy in patients with mildly symptomatic HIV infection. Background on HIV infection; Clinical characteristics of the patients; Data and methods used; Results and conclusions.
- CLEAN AND SOBER. // Advocate;6/28/94, Issue 658, p57
Reports on the effects of ethanol, marijuana and tobacco use in patients on AZT monotherapy, AZT-ddC combination therapy and ddl monotherapy. Increase in amylase levels.
- A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean-Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc // Journal of Infectious Diseases;5/1/2002, Vol. 185 Issue 9, p1251
This randomized study evaluated the efficacy and tolerability of continued treatment with protease inhibitor plus nucleoside-analogue combination regimens (n = 79) or a change to the simplified regimen of abacavir-lamivudine-zidovudine (n = 84) in patients with suppressed human immunodeficiency...
- Zidovudine for early HIV infection: yes, no, maybe. Roberts, John C. // BMJ: British Medical Journal (International Edition);8/7/93, Vol. 307 Issue 6900, p346
Focuses on the recommendation for the use of zidovudine for patients with HIV infections in France and Great Britain. Role of zidovudine on the delayed onset of the disease; Determination of CD4 lymphocyte counts in zidovudine treatment; Benefits of zidovudine therapy.
- NEWS IN BRIEF: IDAHO. // Advocate;3/13/90, Issue 546, p28
Reports a change in an Idaho rule that would qualify HIV-positive persons for government subsidized AZT treatment.
- South Africa: Setting the wrong example. // Nature Medicine;Jan1999, Vol. 5 Issue 1, p1
Examines the decision of South Africa not to treat HIV-positive pregnant women with the anti-viral drug AZT. Estimated number of infants who acquired HIV from their mothers in 1997; Reduction of infant infection mortality; Efficacy, economic and cultural issues.
- Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients. Salgo, M.; Stellbrink, H-J.; Bragman, K.; Hawkins, D.A.; Clumeck, N.; Cooper, D.A.; Myers, R.J.; Delfraissy J.-F.; Gill, M.J.; Ramirez-Ronda, C.; Vella, S. // Clinical Drug Investigation;2000, Vol. 20 Issue 5, p295
Background: PISCES (SV14604) was the largest study of antiretroviral therapy to assess clinical end-points. The study data provides a repository of important information, much of which remains relevant today. This paper reviews the results of the PISCES study, placing the findings in context...
- AZT for Mild Symptoms. Helquist, Michael // Advocate;9/12/89, Issue 533, p24
Reports on the results of a U.S. government study on the effect of the drug AZT on the outcome of HIV infection. Profile of the ideal candidate for AZT use; Absence of side effects on users with mild symptoms.
- Zidovudine resistant HIV. Jeffries, D.J. // BMJ: British Medical Journal (International Edition);4/29/89, Vol. 298 Issue 6681, p1132
Examines efficacy of the nucleoside analogue 3'-azido-3'-deoxythymidine (zidovudine, AZT) on HIV treatment. Suppression of virus replication following treatment; Decrease on sensitivity of viral isolates among patients; Correlation between sensitivity testing and plasma concentration of zidovudine.